PL2607362T3 - Karboksylany piperydyny i piperazyny jako inhibitory FAAH - Google Patents
Karboksylany piperydyny i piperazyny jako inhibitory FAAHInfo
- Publication number
- PL2607362T3 PL2607362T3 PL13160373T PL13160373T PL2607362T3 PL 2607362 T3 PL2607362 T3 PL 2607362T3 PL 13160373 T PL13160373 T PL 13160373T PL 13160373 T PL13160373 T PL 13160373T PL 2607362 T3 PL2607362 T3 PL 2607362T3
- Authority
- PL
- Poland
- Prior art keywords
- carboxylates
- piperazine
- piperidine
- faah inhibitors
- faah
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 239000003940 fatty acid amidase inhibitor Substances 0.000 title 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical class OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005040197 | 2005-02-17 | ||
JP2005303065 | 2005-10-18 | ||
EP06713839.6A EP1849773B1 (en) | 2005-02-17 | 2006-02-16 | Piperazine derivatives for the treatment of urinary incontinence and pain |
EP13160373.0A EP2607362B1 (en) | 2005-02-17 | 2006-02-16 | Piperidine and piperazine carboxylates as FAAH inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2607362T3 true PL2607362T3 (pl) | 2015-05-29 |
Family
ID=36916476
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06713839T PL1849773T3 (pl) | 2005-02-17 | 2006-02-16 | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
PL13160373T PL2607362T3 (pl) | 2005-02-17 | 2006-02-16 | Karboksylany piperydyny i piperazyny jako inhibitory FAAH |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06713839T PL1849773T3 (pl) | 2005-02-17 | 2006-02-16 | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
Country Status (20)
Country | Link |
---|---|
US (3) | US7919495B2 (pl) |
EP (2) | EP2607362B1 (pl) |
JP (1) | JP4702361B2 (pl) |
KR (3) | KR101065979B1 (pl) |
CN (1) | CN101160287B (pl) |
AU (3) | AU2006215080B2 (pl) |
BR (1) | BRPI0608205B8 (pl) |
CA (1) | CA2598294C (pl) |
CY (2) | CY1114709T1 (pl) |
DK (2) | DK2607362T3 (pl) |
ES (2) | ES2528674T3 (pl) |
IL (1) | IL184998A (pl) |
MX (1) | MX2007010076A (pl) |
NO (1) | NO20074697L (pl) |
PL (2) | PL1849773T3 (pl) |
PT (2) | PT2607362E (pl) |
RU (3) | RU2408580C2 (pl) |
SI (2) | SI2607362T1 (pl) |
TW (3) | TW200640864A (pl) |
WO (1) | WO2006088075A1 (pl) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
WO2007005510A1 (en) | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
EP2308840A1 (en) * | 2005-06-30 | 2011-04-13 | Prosidion Limited | GPCR agonists |
AU2006264651A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
JP2009527479A (ja) * | 2006-02-17 | 2009-07-30 | アバロン ファーマシューティカルズ,インコーポレイテッド | ヒドロキシピペリジン誘導体とその使用 |
WO2008023720A1 (fr) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé |
KR101181194B1 (ko) | 2006-10-18 | 2012-09-18 | 화이자 프로덕츠 인코포레이티드 | 바이아릴 에터 우레아 화합물 |
JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2受容体拮抗薬およびその使用 |
PT2195293E (pt) | 2007-08-22 | 2014-01-21 | Astrazeneca Ab | Derivados da ciclopropilamida |
CN102056900A (zh) * | 2008-04-07 | 2011-05-11 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
US20090325964A1 (en) * | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
TWI434842B (zh) * | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
MX2011004704A (es) | 2008-11-06 | 2011-05-30 | Astellas Pharma Inc | Compuesto de carbamato o sal del mismo. |
EA020548B1 (ru) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
MX2012006964A (es) | 2009-12-17 | 2012-07-17 | Boehringer Ingelheim Int | Nuevos antagonistas del receptor ccr2 y usos de los mismos. |
WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
AU2010344973B2 (en) | 2010-02-05 | 2016-06-16 | Merck Patent Gmbh | Hetaryl-[1,8]naphthyridine derivatives |
RU2012136148A (ru) | 2010-02-18 | 2014-03-27 | Астразенека Аб | Новая кристаллическая форма производного циклопропилбензамида |
WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
US8841313B2 (en) | 2010-05-17 | 2014-09-23 | Boehringer Ingelheim International Gmbh | CCR2 antagonists and uses thereof |
EP2576542B1 (en) | 2010-05-25 | 2015-04-22 | Boehringer Ingelheim International GmbH | Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases |
US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なccr2拮抗薬 |
AR091888A1 (es) * | 2012-07-24 | 2015-03-11 | Bial Portela & Ca Sa | Compuestos de urea y su uso como inhibidores de enzimas |
DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
JP6917910B2 (ja) | 2015-07-02 | 2021-08-11 | セントレクシオン セラピューティクス コーポレイション | (4−((3r,4r)−3−メトキシテトラヒドロ−ピラン−4−イルアミノ)ピペリジン−1−イル)(5−メチル−6−(((2r,6s)−6−(p−トリル)テトラヒドロ−2h−ピラン−2−イル)メチルアミノ)ピリミジン−4イル)メタノンクエン酸塩 |
AU2018236161B9 (en) * | 2017-03-13 | 2022-03-31 | Lundbeck La Jolla Research Center, Inc. | Dual MAGL and FAAH inhibitors |
SG10201802129QA (en) * | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
MX2021002923A (es) * | 2018-09-13 | 2021-09-08 | Celgene Corp | (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso. |
JP7473565B2 (ja) * | 2019-01-28 | 2024-04-23 | ミトコンドリア エモーション, インク. | マイトフュージン活性化物質及びその使用方法 |
WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200462B (pl) | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
SK282252B6 (sk) | 1995-01-11 | 2001-12-03 | Samjin Pharmaceutical Co., Ltd. | Piperazínové deriváty a farmaceutický prostriedok s ich obsahom |
US5870472A (en) | 1996-11-12 | 1999-02-09 | General Instrument Corporation | Dynamic relocation of the service data channel |
US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
IL137517A0 (en) | 1998-01-27 | 2001-07-24 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl factor xa inhibitors |
EP1185275A1 (en) | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
DE60041584D1 (de) | 1999-07-28 | 2009-04-02 | Aventis Pharma Inc | Substituierte oxoazaheterozyclische verbindungen |
PT1337271E (pt) | 2000-11-30 | 2005-01-31 | Pfizer Prod Inc | Combinacao de agonistas de gaba e inibidores de sorbitol desidrogenase |
ATE348829T1 (de) | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
AU2002351731A1 (en) | 2001-12-14 | 2003-06-30 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
JP2003192659A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | フェニル尿素誘導体 |
EP1461311A2 (en) | 2001-12-26 | 2004-09-29 | Bayer HealthCare AG | Urea derivatives as vr1-antagonists |
PL373970A1 (pl) | 2002-02-08 | 2005-09-19 | Bristol-Myers Squibb Company | (Oksymo) karbamoilowe inhibitory hydrolazy amidówkwasów tłuszczowych |
FR2843964B1 (fr) | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
EP1558591B1 (en) * | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
JP2006527212A (ja) | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート |
BRPI0410657A (pt) | 2003-06-12 | 2006-06-20 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
CA2525207A1 (en) | 2003-06-12 | 2004-12-23 | Novo Nordisk A/S | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
FR2865205B1 (fr) | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
CN101175724B (zh) * | 2005-05-19 | 2011-12-07 | 安斯泰来制药有限公司 | 吡咯烷衍生物或其盐 |
-
2006
- 2006-02-16 ES ES13160373.0T patent/ES2528674T3/es active Active
- 2006-02-16 JP JP2007503689A patent/JP4702361B2/ja active Active
- 2006-02-16 RU RU2009121774/04A patent/RU2408580C2/ru active
- 2006-02-16 TW TW095105236A patent/TW200640864A/zh not_active IP Right Cessation
- 2006-02-16 PL PL06713839T patent/PL1849773T3/pl unknown
- 2006-02-16 SI SI200631896T patent/SI2607362T1/sl unknown
- 2006-02-16 TW TW098121395A patent/TWI385164B/zh not_active IP Right Cessation
- 2006-02-16 CA CA2598294A patent/CA2598294C/en active Active
- 2006-02-16 RU RU2007134441/04A patent/RU2376289C2/ru active
- 2006-02-16 MX MX2007010076A patent/MX2007010076A/es active IP Right Grant
- 2006-02-16 TW TW098121399A patent/TWI385152B/zh not_active IP Right Cessation
- 2006-02-16 WO PCT/JP2006/302698 patent/WO2006088075A1/ja active Application Filing
- 2006-02-16 PL PL13160373T patent/PL2607362T3/pl unknown
- 2006-02-16 DK DK13160373.0T patent/DK2607362T3/en active
- 2006-02-16 EP EP13160373.0A patent/EP2607362B1/en active Active
- 2006-02-16 AU AU2006215080A patent/AU2006215080B2/en not_active Ceased
- 2006-02-16 BR BRPI0608205A patent/BRPI0608205B8/pt active IP Right Grant
- 2006-02-16 CN CN200680004214XA patent/CN101160287B/zh active Active
- 2006-02-16 SI SI200631681T patent/SI1849773T1/sl unknown
- 2006-02-16 EP EP06713839.6A patent/EP1849773B1/en active Active
- 2006-02-16 PT PT13160373T patent/PT2607362E/pt unknown
- 2006-02-16 RU RU2009121775/04A patent/RU2408581C2/ru active
- 2006-02-16 KR KR1020097011569A patent/KR101065979B1/ko active IP Right Grant
- 2006-02-16 KR KR1020077020924A patent/KR101063663B1/ko active IP Right Grant
- 2006-02-16 ES ES06713839T patent/ES2433290T3/es active Active
- 2006-02-16 PT PT67138396T patent/PT1849773E/pt unknown
- 2006-02-16 KR KR1020097011570A patent/KR101063585B1/ko active IP Right Grant
- 2006-02-16 DK DK06713839.6T patent/DK1849773T3/da active
- 2006-02-16 US US11/816,508 patent/US7919495B2/en active Active
-
2007
- 2007-08-02 IL IL184998A patent/IL184998A/en not_active IP Right Cessation
- 2007-09-14 NO NO20074697A patent/NO20074697L/no not_active Application Discontinuation
-
2009
- 2009-08-19 US US12/543,659 patent/US7915261B2/en active Active
- 2009-08-19 US US12/543,690 patent/US7919494B2/en active Active
-
2010
- 2010-06-04 AU AU2010202348A patent/AU2010202348B2/en not_active Ceased
- 2010-06-04 AU AU2010202347A patent/AU2010202347B2/en not_active Ceased
-
2013
- 2013-12-04 CY CY20131101099T patent/CY1114709T1/el unknown
-
2015
- 2015-02-25 CY CY20151100193T patent/CY1116348T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2607362E (pt) | Carboxilatos de piperidina e de piperazina como inibidores de haag | |
SI1910348T1 (sl) | Spojine benzotiazola in azabenzotiazola, uporabne kot kinazni inhibitorji | |
ZA200707650B (en) | Azolylacylguanidines as ß-secretase inhibitors | |
IL176823A0 (en) | Piperidine derivatives as gcs inhibitors | |
ZA200800379B (en) | Glutamate aggrecanase inhibitors | |
HK1114380A1 (en) | Pyrrolopyrazoles as kinase inhibitors | |
ZA200804393B (en) | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | |
GB0403635D0 (en) | Pyridinocarboxamides with improved activity as kinase inhibitors | |
EP1971595A4 (en) | CETP INHIBITORS | |
EP1973889A4 (en) | CETP INHIBITORS | |
ZA200802867B (en) | Fap inhibitors | |
IL185024A0 (en) | Raf inhibitor compounds and methods | |
PL1833816T3 (pl) | Podstawione piperydyny jako inhibitory reniny | |
ZA200700181B (en) | Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors | |
EP1839669A4 (en) | NEW ANGIOGENESEHEMMER | |
HK1107348A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
PL1863803T3 (pl) | Podstawione piperydyny | |
IL186117A0 (en) | Substituted piperidines as renin inhibitors | |
IL189112A0 (en) | NOVEL HETEROCYCLIC NF-kB INHIBITORS | |
ZA200903058B (en) | Heterocyclic derived metalloprotease inhibitors | |
HK1214590A1 (zh) | 哌啶和哌嗪衍生物 | |
EP1951053A4 (en) | CETP INHIBITORS | |
ZA200800672B (en) | Introcatechol derivatives as COMT inhibitors | |
GB0421355D0 (en) | Inhibitors | |
IL188371A0 (en) | Novel piperidine derivatives |